CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Shares withheld for taxes Chief Scientific Officer gave up 12,630 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 11,917 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes Chief Legal Officer gave up 11,395 shares (to pay taxes)
- 4 Planned sale Director sold 10,000 shares at $10.11 ($101,052)
- 4 Grant or award Chief Financial Officer acquired 58,869 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Director sold 10,000 shares at an average $11.56 ($115,588)
- 4 Exercise or conversion Director acquired 36,316 shares (option exercise)
- 4 Grant or award Chief Medical Officer acquired 58,386 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 56,446 shares (grant or award)
- 4 Planned sale Director sold 10,100 shares at an average $13.51 ($136,454)
- 4 Planned sale Chief Executive Officer sold 100 shares at $15.00 ($1,500)
- 4 Grant or award Chief Scientific Officer acquired 60,230 shares (grant or award)
- 4 Planned sale Director sold 11,000 shares at $15.05 ($165,495)
- 4 Planned sale Chief Executive Officer sold 9,648 shares at $15.04 ($145,106)
- 4 Planned sale Director sold 27,590 shares at an average $13.88 ($382,934)
- 4 Planned sale Director sold 2,410 shares at an average $13.77 ($33,192)
- 4 Grant or award Chief Executive Officer acquired 56,458 shares (grant or award)
- 4 Planned sale Director sold 10,000 shares at $11.27 ($112,691)
Page 4 of 22 · 435 filings